Transforming the Diagnosis and Treatment of Synucleinopathies
Advancing early detection and targeted therapies for Parkinson’s disease and related synucleinpathies through next-generation antibody technology.
Innovating Diagnosis and Treatment Outcomes
- Proprietary immunoassays and SAIA for early, sensitive detection of pathological a-synuclein.
- Targeted antibody programs addressing disease-driving synuclein species.
- Translational collaborations advancing precision neurodegenerative care.
Pioneering Integrated Solutions for Synucleinopathies
QABY Biotech delivers coordinated diagnostic and therapeutic platforms to address critical unmet needs in synucleinopathy care.
Advanced Diagnostic Platforms
Proprietary immunoassays and SAIA technology enabling early, specific detection of pathological α-synuclein species across CSF and peripheral biofluids.
Targeted Therapeutic Innovations
Next-generation antibody formats engineered to selectively target disease-driving α-synuclein species and overcome limitations of prior candidates.
Research-Driven Collaboration
Partnering with leading clinical, academic, and industry groups to accelerate biomarker validation and therapeutic development in synucleinopathies.
Integrated Theranostic Approach
Uniting diagnostics and therapeutics to enable companion diagnostic (CDx) development, patient stratification, and personalized treatment strategies.